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Since its first description in 1990, SELEX (Systematic Evolution of 
Ligands by Exponential enrichment) technology has been widely used as 
an in vitro selection method to evolve nucleic acid ligands, called 
aptamers, with new functionalities. We have prepared single-stranded 
DNA aptamers against non-metabolizable sugars and peptide using 
SELEX, with the ultimate goal of developing biosensors for the intestinal 
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Oligonucleotides are very attractive compounds for combinatorial 
chemistry. They can easily be amplified by polymerase chain reaction 
(PCR) or in vitro transcription, and can fold into defined secondary and 
tertiary structures. The random-sequence oligonucleotide libraries with 
about 1015 different molecules are able to be synthesized and screened in 
parallel for a particular functionality. In 1990, Tuerk and Gold [1] 
introduced a new in vitro selection and amplification method, named 
SELEX (Systematic Evolution of Ligands by EXponential enrichment). 
They used a combinatorial oligonucleotide library to select RNA 
oligonucleotides that can very tightly and selectively bind to T4 DNA 
polymerase gp43. In the same year, Ellington and Szostak [2] separated 
RNA oligonucleotides from a random-sequence RNA library with a 
similar selection procedure, which can recognize and bind small organic 
dyes (Cibacron Blue, Reactive Blue 4). They named these selected 
individual RNA molecules aptamers, derived from the Latin word 
“aptus”, which means “to fit”. Two years later, the single-stranded DNA 
(ssDNA) aptamers from a chemically synthesized pool of 
random-sequence DNA molecules were successfully selected [3]. 
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The functionality of aptamers is based on their stable three-dimensional 
structure, which is dependent on the primary sequence, the length of the 
nucleic acid molecule (smaller than 100 nt), and the environmental 
conditions. Typical structural motives of aptamers are stems, internal 
loops, bulges, hairpin structures, tetra loops, pseudoknots, triplicates, 
kissing complexes, and G-quadruplex structures. In the presence of the 
target, the aptamers undergo adaptive conformational changes, and their 
three-dimensional folding structures create one or several specific binding 
sites for the target (Fig. 1). The intermolecular interactions between 
aptamer and target are characterized as a combination of complementarity 
in shape, stacking interactions between aromatic compounds and the 
nucleobases of the aptamers, electrostatic interactions between charged 
groups, and hydrogen bondings [4-6]. Aptamers can possess strong 
affinities to target molecules, with dissociation constants (Kd) down to 
nanomolar or picomolar range.  
 
Fig. 1.  Schematic of the functionality of aptamers 
 
Currently, nucleic acid aptamers have been selected for more than 150 
targets, including small molecules such as cocaine [7] and aspartame [8], 
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growth factors [9-12], peptides [13, 14], toxins [15, 16], viral proteins [17, 
18], even cells and bacteria [19-21]. The SELEX technology has been 
widely used in molecular biological, pharmaceutical, and medical 
research, and often been modified to make the selection process more 
efficient and less time consuming, and to select aptamers with particular 
binding features for different targets and for different applications. 
 
Since its first introduction by Caridis [22] about 30 years ago, change in 
intestinal permeability (IP) has been widely applied to evaluate and 
monitor the intestinal mucosa damage, infection, and many other diseases. 
For measuring the IP, the dual sugars probes, lactulose (L) and mannitol 
(M), have been commonly used. Lactulose and mannitol are absorbed in 
different regions of the gastrointestinal tract and excreted nonmetabolized 
in the urine. The small molecular M is thought to permeate the mucosa 
mainly via the transcellular pathway (small pores), whereas the larger 
molecular L enter through the paracellular pathway (large pores). The 
ratio of the excretion percentage L% to M% (L/M) in urine is considered 
as a direct, sensitive and accurate indicator of IP. Under the infection, 
damaged, and invasive ways, the width of the intercellular channels 
enlarges, which leads to the high throughput for the large molecular L. 
Usually the L/M ratios for patients are higher than those for the healthy 
individuals. In addition, one nonmetabolized peptide (HHH-33mer 
3 
peptide) can substitute for sugars in IP test [23].  
 
Fig. 2. The molecular structure of mannitol and lactulose 
 
In the present study, I have selected aptamers against the HHH-33mer 
peptide, lactulose and mannitol. Additionally, I propose the design of 
aptamer-based biosensors for an improved intestinal permeability test. 
 
1.1 SELEX Technology 
1.1.1 General principle 
Aptamer can be obtained via isolation from synthetic combinatorial 
libraries of nucleic acids through the in vitro selection process SELEX. 
The basic steps of a SELEX process are presented in Fig. 3. At the 
beginning of a typical SELEX process, one random-sequence DNA 
oligonucleotide library consisting of about 1013 to 1015 different sequence 
motifs is chemically synthesized [24]. For the selection of DNA aptamers, 
this library can be used without any pretreatments, whereas a conversion 
into an RNA library has to be accomplished before starting an RNA 
SELEX process with RT-PCR. In either case, the randomized RNA or 
DNA pool is necessary to be incubated directly with the targets. The 
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aptamer-target compounds are subsequently partitioned from the unbound 
and weakly bound oligonucleotides. This is the most crucial aspect of an 
aptamer selection process, which strongly affects binding features of the 
aptamers to be selected. Target-bound oligonucleotides are eluted and 
amplified by PCR (DNA SELEX) or reverse transcription RT-PCR (RNA 
SELEX). After the PCR step, the double-stranded PCR product has to be 
transformed into a new oligonucleotide pool by separating the 
complementary ssDNA or by in vitro transcription and subsequently 
purifying the synthesized RNA. However, with the unidirection PCR, the 
ssDNA pool can be directly achieved. The fresh and enriched pool of 
selected oligonucleotides is used in the next round of SELEX. By 
iterative cycles of selection and amplification, the members of initial 
random-sequence oligonucleotide pool are reduced to relatively few 
sequences with the highest affinity and specificity for the target. The 
number of rounds for SELEX depends on a great variety of aspects, such 
as target characteristic and concentration, design of the initial 
random-sequence oligonucleotide library, selection conditions, ratio of 
target molecules to oligonucleotides, and the efficiency of the partition 
method. 
 
After the amplification step of the last SELEX round, the PCR products 
are cloned to get individual aptamer clones from the selected pool. These 
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individual aptamer clones would be sequenced and sequence analyzed. 
Typical aptamer clones are chosen and used in binding assays to 
characterize their binding features in more detail, including the affinities 
and specificities. To narrow down the minimal binding region within the 
aptamer sequence, mutation and truncation experiments can be 
performed. 
 
Fig. 3 In vitro selection of aptamers using SELEX technology. Starting point of each SELEX 
process is a synthetic random-sequence DNA oligonucleotide library consisting of ~1015 members 
of ssDNA. This library can be used directly for the selection of DNA aptamers. For the selection 
of RNA aptamers the library has to be transferred into an RNA library. The SELEX procedure is 
characterized by the iterative steps consisting of selection (binding, partition, and elution), 
amplification and conditioning. In the first SELEX round, the library and the target molecules are 
incubated 1 h for binding. Unbound and weakly bound oligonucleotides are removed by several 
stringent washing steps from the binding complexes. The target-bound oligonucleotides are eluted 
and subsequently amplified by PCR or RT-PCR. The new enriched pool of selected 
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oligonucleotides is generated from the PCR products (DNA SELEX) or by in vitro transcription 
(RNA SELEX), and then used for the next selection round. Generally 6 to 20 SELEX rounds are 
necessary for the selection of highly affinitive, target-specific aptamers. After the last SELEX 
round, the enriched aptamer pool is cloned and several individual aptamers have to be sequence 
analyzed. 
 
The SELEX process for the selection of target-specific aptamers is a 
universal process that consists of five main steps (binding, partition, 
elution, amplification and conditioning). However there is no 
standardized SELEX protocol for all targets. The design of the SELEX 
process and the specific selection conditions depends on several aspects, 
e.g. the target itself, the oligonucleotide library or the desired features and 
application of the aptamers to be selected. 
 
 
1.1.2 Advantages of aptamers 
Antibodies have been widely used in the majority of biomedical 
applications. Compared with antibodies, aptamers are an emerging class 
of molecules with several important advantages [25-29]. First, aptamers 
are efficient at binding not only to large molecules, such as proteins and 
cells, but also to small molecules, such as nucleotides, organic dyes, 
amino acids, and even metal ions, while antibodies are generally 
competent in binding to larger molecules. Second, aptamers are selected 
in vitro SELEX, and therefore can be used to select a wide range of 
targets, including toxic or non-immunogenic molecules. Moreover, the 
selection process can be performed under non-physiological condition, 
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such as extremely high or low temperatures or pH. These properties are 
difficult for antibodies to be obtained, since they are produced in vivo. 
Third, once an aptamer sequence is confirmed, it can be achieved in a 
large amount through chemical synthesis which is cost-effective and has 
minimal batch to batch difference in activity. Meanwhile it is much easier 
to chemically modify aptamers with a variety of fluorophores, 
electrochemical or Raman reporters, functionalities such as primary 
amine, thiol groups on either 5' or 3' end, on the bases, or on the 
backbone of DNA [30].  
 
Furthermore, aptamers can be combined into one, two or three 
dimensional nanostructures [31-36], which can also be used for clinical 
and diagnostic applications [37-39]. In designing microarrays, aptamers 
can provide additional advantages. Since the size of aptamers is much 
smaller (~1-2 nm, <10 kDa) than those of antibodies (~10 nm and ~155 
kDa), aptamers have higher surface density and less steric hindrance, 
which helps to increase the binding yield. In addition, for nucleic 
acid-immobilized surfaces, non-specific adsorption happens much less 
compared to protein immobilized surfaces [40], which facilitates the 
engineering process. Finally, aptamers are much more stable to heat [41], 
pH, and organic solvents [42] than antibodies. These properties make 




Materials and Methods 
 
2.1 Material preparation 
2.1.1 HHH-33mer peptide 
Peptide was prepared by standard peptide coupling automated synthesis 
and supplied by GL biochem (shanghai, China) Ltd. The purity and 
concentration was confirmed by HPLC. The sequence of the 33-mer 
peptide is LQLQPEPQPHLPYPQPHLPYPQPHLPYPQPQPF. 
 
2.1.2 HiTrap NHS-activated column 
HiTrap NHS-activated column (GE Healthcare) is made of polypropylene, 
which is biocompatible and non-interactive with biomolecules. It is 
designed for the covalent coupling of ligands containing primary amino 
group. The medium is based on highly cross-linked agarose beads with 6 
atoms spacer arms attached to the matrix by epichlorohydrine and 
activated by N-hydroxysuccinimide. The substitution level is ~10 µmol 
NHS-groups/ml medium.  
 
2.1.3 ssDNA library pool 
A degenerate DNA oligonucleotide library containing a 25-base random 
sequence flanked by primers on either ends, was used as starting point for 
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the aptamer selections. The sequence of the library was 5’-GGG AGA 
CAA GAA TAA ACG CTC AA-(25N)-TTC GAC AGG AGG CTC ACA 
ACA GGC-3’. The forward primer was 5’-GGG AGA CAA GAA TAA 
ACG CTC AA-3’ and the reverse primer was 5’-GCC TGT TGT GAG 
CCT CCT GTC GAA-3’. 
 
To enrich the presence of all DNA aptamer species in the original library, 
an ssDNA pool was generated from the original synthetic pool by 
large-scale unidirectional PCR. 1 mL PCR culture (separate to ten PCR 
tubes) was prepared: aptamer library 4 nmol (AITBIOTECH Pte Ltd, 
Singapore), forward primer 200 nmol (AITBIOTECH Pte Ltd, Singapore), 
reverse primer 4 nmol (AITBIOTECH Pte Ltd, Singapore), 10X PCR 
buffer with MgCl2 100 µL (Sigma), dNTPs at 25 mM of each nucleotide 
100 µL (iDNA, Singapore), MgCl2 15 mM 40 µL (Merck), Taq DNA 
polymerase 20 units (10 units initially plus 10 additional units on 45th 
cycle to ensure enzymatic activity; Sigma). Ninety-nine rounds of 
amplification were performed at 94 ℃ denaturing (1.5 min), 56 ℃ 
annealing(0.5 min) and 72 ℃ extension(1.5 min) in a thermo cycler; a 





2.2 Experiment Part 
2.2.1 Peptide coupling with column 
2 mg HHH-33mer peptide was dissolved in 1mL coupling buffer (0.2 M 
NaHCO3, 0.5 M NaCl, pH 8.3). After incubation for 15 min, the solution 
was injected into 1 mL NHS-activated column. The column was sealed 
and stored for 1 h at room temperature. 3 mL coupling buffer was used to 
wash away excess ligand. To deactivate any excess active group that have 
not coupled to the ligand and wash out the non-specifically bound ligands, 
the column should be wash thoroughly with at least three cycles of 
alternating pH. Each cycle should consist of a wash with 0.5 M 
ethanolamine (Merck) buffer pH 8.3 containing 0.5 M NaCl (Merck) 
followed by a wash with 0.1 M acetate (Merck) buffer pH 4.0 containing 
0.5 M NaCl. 
 
2.2.2 In vitro Selection of Aptamers against the HHH-33mer 
peptide 
30 nmol amplified library was mixed in 1X binding buffer (100 mM 
NaCl, 5 mM MgCl2 , pH 7.2) to a final volume of 1 mL and allowed to 
incubate in the prepared column at room temperature for 1 h. After 
incubation, the column was washed with 5 mL of 1X wash buffer (150 
mM NaCl, 5 mM MgCl2, pH 7.2). The column was finally washed with 3 
mL of 1X elution buffer (1.5 M NaCl, 5 mM MgCl2, pH 7.2). The eluted 
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fraction was further desalted using a water-equilibrated PD-10 size 
exclusion column (GE Healthcare) and freeze-dried. 
 
The lyophilized aptamers were re-amplified using unidirectional PCR. 
PCR mixtures (100 µL) contained forward primer 400 pmol, reverse 
primer 10 pmol, 10X PCR buffer 10 µL and dNTPs at 10 mM per 
nucleotide 4 µL, MgCl2 15 mM 4.5 µL and Taq DNA polymerase (native 
enzyme) 2 units. Ninety-nine rounds of amplification were performed at 
94℃  denaturing (1.5 min), 56℃  annealing (0.5 min) and 72℃ 
extension (1.5 min) in a thermo cycler; a final extension step was 
included at 72 ℃ for 10 min and soak at 4 ℃. 
 
Selected aptamers were used in consecutive rounds of selection and 
amplification following the same procedure for 20 rounds. After selection, 
the pool of DNA generated from the selections was ligated into a 
thymidine-overhang vector using a TA Cloning kit (Invitrogen). 
Individual transformants were grown overnight in LB (1st BASE, 
Singapore) with 120 µg/mL of ampicillin (Sigma), and DNA isolated 
using a Plasmid Mini kit (Qiagen). Finally, the plasmids were sent to 






3. Results and discussion 
 
3.1 Selection of aptamers against HHH-33mer peptide 
Selection of ssDNA aptamers with the ability to recognize HHH-33mer 
peptide was performed using affinity chromatography matrices from a 
pool of 425 (~1015) different oligonucleotide molecules with a 25-base 
random region flanked by two fixed primer regions on both sides. The 
HHH-33mer peptide was synthesized and immobilized on a 
functionalized Sepharose in an affinity chromatography column as targets 
for SELEX. The synthetic library was amplified for a starting pool of 
ssDNAs, in which each species was represented by a large number of 
molecules, ensuring that no potential high-binding species was lost at the 
early stages of selection due to experimental procedures. The pool was 
incubated with the HHH-33mer peptide in the affinity chromatography 
column for 1 h at room temperature, non-binding or weakly binding 
species were washed from the column during the wash step, and binding 
aptamers were eluted with high salt concentration (1.5 M NaCl). The 
constant primer regions allowed the amplification of binding species by 
PCR, which were subsequently returned to the matrix for the next SELEX 
step. At each successive round the highest binding species displaced 
competitive binding with the weaker ligands in the column, which 
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resulted in a limited pool of high-affinity molecules. Twenty consecutive 
rounds of selection were carried out and after the 15th and 20th round, the 
aptamers were subsequently cloned and 50 or more clones were analyzed 
and sequenced. The sequences were sorted and aligned using the Bioedit 
sequence alignment editor (Isis Pharmaceuticals, Carlsbad, Calif., USA). 
The sequences (Table 1) were compared to each other to identify 
conserved regions. 
Table 1. Aptamer sequences from the selection against HHH-33mer peptide 






































































A total of 32 sequences from 15th and 20th rounds of aptamer pool were 
obtained, 30 of 32 with 25-base pair length. With this collection of 
sequences, there were 4 similar families and 6 specifics as show above. In 
addition, many of the sequences contain a high percentage of C and G 
bases, especially at their 5’ and 3’ ends. This suggests the presence of 








CACGCAGGCAGGACGGACACGTTGG        CACGCAGGCAGGATGGACACGTTGG 




   
CGCGACGTGACGTGACGG_TGCGTGCA 





























Fig. 4 The secondary structure of aptamers against HHH 33-mer peptide. Structures were 
predicted using UNAFold [43]. 
 
There were two main kinds of hairpin secondary structures, containing 
two loop structures, in the predicted energetically favorable secondary 
structures of HHH-33mer peptide aptamers at room temperature. The 
loop secondary structure perhaps accounts for the superior binding to the 
peptide target. 
Because of the maintain of the isothermal titration calorimetry (iTC), the 
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measure of dissociation constants (Kd) value has been delayed to be 
operated. The work has been transferred to Roopsha Brahma with Surface 
Plasmon Resonance (SPR) test. 
 
3.2 Design of aptamer-based biosensors  
The purpose of the selection of aptamer for intestinal permeability test is 
the development of the new detection method. Aptamers can be easily 
modified with variety of organic dyes. Thus fluorophore-based detection 
method for aptamers has been the most widely demonstrated [44-47]. 
And quantum dots (QDs) and gold nanoparticles are good type of 
fluorescent nanomaterials with several unique optical properties [48-50]. 
Compared to organic fluorescent dyes, QDs are more photostable and the 
wavelength of the emitted light can be controlled by changing their size 
and composition of materials. Moreover, QDs have very broad excitation 
range but sharp emission, which make it possible to excite different QDs 
with single wavelength and yet result in variety of emission wavelengths.  
 
Based on my knowledge and research, I just design several biosensors 









QDs 1 QDs 2
Target 2
 
Fig. 5  Biosensor mode based on aptamers and QDs. The excitation wavelengths of QDs 1 and 
QDs 2 are separative. However, the emission wavelength of QDs 1 is in the range of the excitation 
wavelength of QDs 2. First, these QDs are quenched with different quenchers. In the presence of 
targets (Target 1 is main.), the QDs are released. In the light of QDs 1 wavelength, the 
Fluorescence Resonance Energy Transfer (FRET) occurs between QDs 1 and QDs 2. Base on the 

















Aptamer-based biosensors are rather promising. They can be used to 
detect proteins and low-molecular-weight compounds with high 
sensitivity and selectivity, comparable and even higher than   
antibody-based assay. Aptamers can be modified by various ligands and 
indicator groups. Thus, they can be immobilized on solid support of 
different types. Various indicators (optical or electrical) allow us to use 
various methods for detection of aptamer-ligand interactions, including 
electrochemical and optical methods. 
 
In my project, I have finished the selection of aptamers for intestinal 
permeability test, and the initial design of several biosensor modes based 
on aptamers conjugated with quantum dots. The further work will 












1. Tuerk, C., Gold, L., Systematic evolution of ligands by exponential enrichment: RNA ligands 
to bacteriophage T4 DNA polymerase. Science 249 (1990) 505. 
 
2. Ellington, A.D., Szostak, J.W., In vitro selection of RNA molecules that bind specific ligands. 
Nature 346 (1990), 81. 
 
3. Ellington, A.D., Szostak, J.W., Selection in vitro of single-stranded DNA molecules that fold 
into specific ligand-binding structures. Nature 355 (1992) 850. 
 
4. Patel, D.J., Structural analysis of nucleic acid aptamers. Curr. Opin. Chem. Biol. 1 (1997) 32. 
 
5. Patel, D.J., Suri, A.K., Jiang, F., Jiang, L.C., Fan, P., Kumar, R.A., Nonin, S., Structure, 
recognition and adaptive binding in RNA aptamer complexes. J. Mol. Biol. 272 (1997) 645. 
 
6. Hermann, T., Patel, D.J., Adaptive recognition by nucleic acid aptamers. Science 287 (2000) 
820. 
 
7. Stojanovic, M.N., Prada, P. de., Landry, D.W., Fluorescent Sensors Based on Aptamer 
Self-Assembly, J. Am. Chem. Soc. 122 (2000) 11547. 
 
8. Saitoh, H., Nakamura, A., Kuwahara, M., Ozaki, H., Sawai, H., Modified DNA Aptamers 
against Sweet Agent Aspartame, Nucl. Acids Res. Suppl. 2 (2002) 215. 
 
9. Jellinek, D., Green, L.S., Bell, C., Lynott, C.K., Gill, N., Vargeese ,C., Kirschenheuter, G., 
McGee, D.P.C., Abesinghe, P., et al., Potent 2'-Amino-2'-Deoxypyrimidine RNA Inhibitors of 
Basic Fibroblast Growth Factor, Biochemistry 34 (1995) 11363. 
 
10. Pagratis, N.C., Bell, C., Chang, Y.-F., Jennings, S., Fitzwater, T., Jellinek, D., Dang, C., 
Potent 2'-Amino-, and 2'-Fluoro-2'-Deoxyribonucleotide RNA Inhibitors of Keratinocyte 
Growth Factor, Nat. Biotechnol. 15 (1997) 68. 
 
11. Ruckman, J., Green, L.S., Beeson, J., Waugh, S., Gillette, W.L., Henninger, D.D., 
Claesson-Welsh, L., Janjic, N., 2'-Fluoropyrimidine RNA-Based Aptamers to the 165-Amino 
Acid Form of Vascular Endothelial Growth Factor (VEGF165). Inhibition of Receptor 
Binding and VEGF-Induced Vascular Permeability through Interactions Requiring the Exon 
7-Encoded Domain, J. Biol. Chem. 273 (1998) 20556. 
 
12. Green, L.S., Jellinek, D., Jenison, R., Oestman, A., Heldin, C.H., Janjic, N., Inhibitory DNA 
Ligands to Platelet-Derived Growth Factor B-Chain, Biochemistry 35 (1996) 14413. 
 
13. Ogawa, A., Tomita, N., Kikuchi, N., Sando, S., Aoyama, Y., Aptamer Selection for the 
24 
Inhibition of Cell Adhesion with Fibronectin as Target, Bioorg. Med. Chem. Lett. 14 (2004) 
4001. 
 
14. Mendonsa, S.D., Bowser, M.T., In Vitro Selection of Aptamers with Affinity for Neuropeptide 
Y Using Capillary Electrophoresis, J. Am. Chem. Soc. 127 (2005) 9382. 
 
15. Tang, J., Xie, J., Shao, N., Yan, Y., The DNA Aptamers That Specifically Recognize Ricin 
Toxin Are Selected by Two in Vitro Selection Methods, Electrophoresis 27 (2006) 1303. 
 
16. Tang, J., Yu, T., Guo, L., Xie, J., Shao, N., He, Z., In Vitro Selection of DNA Aptamer against 
Abrin Toxin and Aptamer-Based Abrin Direct Detection, Biosens. Bioelectron. 22 (2007) 
2456. 
 
17. Jeon, S.H., Kayhan, B., Ben-Yedidia, T., Arnon, R., A DNA Aptamer Prevents Influenza 
Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin, J. Biol. Chem. 
279 (2004) 48410. 
 
18. Koch, T.H., Smith, D., Tabacman, E., Zichi, D.A., Kinetic Analysis of Site-Specific 
Photoaptamer-Protein Cross-Linking, J. Mol. Biol. 336 (2004) 1159. 
 
19. Bruno, J.G., Kiel, J.L., In Vitro Selection of DNA Aptamers to Anthrax Spores with 
Electrochemiluminescence Detection, Biosens. Bioelectron. 14 (1999) 457. 
 
20. Blank, M., Weinschenk, T., Priemer, M., Schluesener, H., Systematic Evolution of a DNA 
Aptamer Binding to Rat Brain Tumor Microvessels. Selective Targeting of Endothelial 
Regulatory Protein Pigpen, J. Biol. Chem. 276 (2001) 16464. 
 
21. Wang, C., Zhang, M., Yang, G., Zhang, D., Ding, H., Wang, H., Fan, M., Shen, B., Shao, N., 
Single-Stranded DNA Aptamers That Bind Differentiated but Not Parental   Cells: 
Subtractive Systematic Evolution of Ligands by Exponential Enrichment, J. Biotechnol. 102 
(2003) 15. 
 
22. Fink, M. P., Gastrointestinal mucosal injury in experimental models of shock, trauma, and 
sepsis. Crit. Care Med. 1991, 19, 627. 
 
23. Bethune, M.T., Crespo-Bosque, M., Bergseng, E., Mazumdar, K., Doyle, L., Sestak, K., Sollid, 
L.M. and Khosla, C., Noninflammatory Gluten Peptide Analogs as Biomarkers for Celiac 
Sprue, Chemistry & Biology, 16 (2009), 868. 
 
24. James,W., Aptamers. In: Meyers, R.A. (Ed.), Encyclopedia of Analytical Chemistry. John 
Wiley & Sons Ltd., Chichester, pp (2000). 4848. 
 
25. Proske, D., Blank, M., Buhmann, R., Resch, A., Aptamers-Basic Research, Drug Development, 
and Clinical Applications, Appl. Microbiol. Biotechnol. 69 (2005) 367. 
25 
 
26. Fichou, Y., Ferec, C., the Potential of Oligonucleotides for Therapeutic Applications, Trends 
Biotechnol. 24 (2006) 563. 
 
27. Ulrich, H., Trujillo, C.A., Nery, A.A., Alves, J.M., Majumder, P., Resende, R.R., Martins, 
A.H., DNA and RNA Aptamers: From Tools for Basic Research Towards Therapeutic 
Applications, Comb. Chem. High T. Scr. 9 (2006) 619. 
 
28. Missailidis, S., Perkins, A., Update: Aptamers as Novel Radiopharmaceuticals: Their 
Applications and Future Prospects in Diagnosis and Therapy, Cancer Biother. Radiopharm. 22 
(2007) 453. 
 
29. Tombelli, S., Minunni, M., Mascini, M., Aptamers-Based Assays for Diagnostics, 
Environmental and Food Analysis, Biomol. Eng. 24 (2007) 191. 
 
30. Lee, J.H., Wernette, D.P., Yigit, M.V., Liu, J., Wang, Z., Lu, Y., Site-Specific Control of 
Distances between Gold Nanoparticles Using Phosphorothioate Anchors on DNA and a Short 
Bifunctional Molecular Fastener, Angew. Chem. Int. Ed. 46 (2007) 9006. 
 
31. Winfree, E., Liu, F., Wenzler, L.A., N.C. Seeman, Design and Self-Assembly of 
Two-Dimensional DNA Crystals, Nature 394 (1998) 539. 
 
32. Goodman, R.P., Schaap, I.A., Tardin, C.F., Erben, C.M., Berry, R.M., Schmidt, C.F., 
Turberfield, A.J., Rapid Chiral Assembly of Rigid DNA Building Blocks for Molecular 
Nanofabrication, Science 310 (2005) 1661. 
 
33. Rothemund, P.W.K., Folding DNA to Create Nanoscale Shapes and Patterns, Nature 440 
(2006) 297. 
 
34. He, Y., Ye, T., Su, M., Zhang, C., Ribbe, A.E., Jiang, W., Mao, C., Hierarchical 
Self-Assembly of DNA into Symmetric Supramolecular Polyhedra, Nature 452 (2008) 198. 
 
35. Seeman, N.C., DNA in a Material World, Nature 421 (2003) 427. 
 
36. Seeman, N.C., The Design and Engineering of Nucleic Acid Nanoscale Assemblies, Curr. 
Opin. Struct. Biol. 6 (1996) 519. 
 
37. Ke, Y., Lindsay, S., Chang, Y., Liu, Y., Yan, H., Self-Assembled Water-Soluble Nucleic Acid 
Probe Tiles for Label-Free Rna Hybridization Assays, Science 319 (2008) 180. 
 
38. Rinker, S., Ke, Y., Liu, Y., Chhabra, R., Yan, H., Self-Assembled DNA Nanostructures for 
Distance-Dependent Multivalent Ligand-Protein Binding, Nat. Nanotechnol 3 (2008) 418. 
 
39. Clark, J., Smith, S.S., Application of Nanoscale Bioassemblies to Clinical Laboratory 
26 
Diagnostics, Adv. Clin. Chem. 41 (2006) 23. 
40. Willner, I., Zayats, M., Electronic Aptamer-Based Sensors, Angew. Chem. Int. Ed. 46 (2007) 
6408. 
 
41. Langer, R., Drug Delivery and Targeting, Nature 392 (1998) 5. 
 
42. Wilson, C., Szostak, J.W., Isolation of a Fluorophore-Specific DNA Aptamer with Weak 




44. Li, J., Lu, Y., A Highly Sensitive and Selective Catalytic DNA Biosensor for Lead Ions, J. Am. 
Chem. Soc. 122 (2000) 10466. 
 
45. Lu, Y., New Transition Metal-Dependent DNAzymes as Efficient Endonucleases and as 
Selective Metal Biosensors, Chem. Eur. J. 8 (2002) 4588. 
 
46. Navani, N.K., Li, Y., Nucleic Acid Aptamers and Enzymes as Sensors, Curr. Opin. Chem. 
Biol. 10 (2006) 272. 
 
47. Park, J. U., Lee, J.H., Paik, U., Lu, Y., Rogers, J.A., Nanoscale Patterns of Oligonucleotides 
Formed by Electrohydrodynamic Jet Printing with Applications in Biosensing and 
Nanomaterials Assembly, Nano Lett. 8 (2008) 4210. 
 
48. Murray, C.B., Norris, D.J., Bawendi, M.G., Synthesis and Characterization of Nearly 
Monodisperse CdE (E=Sulfur, Selenium, Tellurium) Semiconductor Nanocrystallites, J. Am. 
Chem. Soc. 115 (1993) 8706. 
 
49. Alivisatos, A.P., Semiconductor Clusters, Nanocrystals, and Quantum Dots, Science 271 
(1996) 933. 
 
50. Peng, X., Manna, L., Yang, W., Wickham, J., Scher, E., Kadavanich, A., Alivisatos, A.P., 
Shape Control of CdSe Nanocrystals, Nature 404 (2000) 59. 
 
27 
